explore -WSS

explore

author：hotspot 2025-10-02 22:56:59 - browse：61

ADAM FEUERSTEIN/STAT

CHICAGO — Corbus Pharmaceuticals is the second best-performing biotech stock this year, thanks to investor interest in an antibody-drug conjugate candidate, or ADC, called CRB-701 with the potential to be better tolerated than Padcev, an ADC treatment bladder cancer that Pfizer acquired as part of its $43 billion Seagen deal.

On Saturday, Corbus updated results from an early, dose-finding study of CRB-701, showing an overall response rate of 28% from 25 evaluable patients. Closer attention is being paid to the subset of 15 patients treated at three therapeutically active doses, where the overall response rate (all partial tumor shrinkage) was 40%. All of the responses were seen in bladder cancer (where Padcev is approved) and in cervical cancer.

The data, from a study conducted in China, were presented in a poster session at the annual meeting of the American Society of Clinical Oncology.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： NYU radiologists take on the challenge of expensive MRI machines

focus

WSS

California store owner shot dead in dispute over displaying Pride flag: Police

Poor hospice wound care hurts patients and families

Trans patients at the end of life deserve respect and dignity

FDA advisory panel to debate high blood pressure devices

Republicans love RFK Jr. What's that tell us about health in 2024?

National associations that represent hospice owe an apology

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Cancer drug shortages should be causing more outrage

California store owner shot dead in dispute over displaying Pride flag: Police

Peter Hotez and the public health issue of online harassment

Does good food count as health care? Study aims to find out

In age of alternative facts, a scholarly course on calling out crap

NYU radiologists take on the challenge of expensive MRI machines

Alkermes shareholders re

DeSantis wants to import drugs. Biden’s FDA blasted his plan

knowledge

World's first CRISPR

Trans patients at the end of life deserve respect and dignity

PBMs are inflating the cost of generic drugs. They must be reined in

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Astellas still sees hope in its gene therapy after four deaths

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Wikipedia

focus

Wikipedia

hotspot